Natco’s marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner Alvogen has received the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg. Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart). Pfizer Pharmaceuticals Ltd markets this drug under its brand Nitrostat® Sublingual Tablets in the same strengths mentioned above. As per IQVIA data, Nitroglycerin Sublingual Tablets had total annual sales of around USD 77.3 million in the US market, for the year ending 2018.

The release as fetched from its publisher. natcopharma.co.in ↗